Reuters logo
BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)
November 9, 2017 / 5:52 PM / a month ago

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

Nov 9 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF)

* SEATTLE GENETICS INC - ‍FDA ALSO GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ADCETRIS​

* SEATTLE GENETICS INC - ‍PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE FOR ADCETRIS WAS DECEMBER 16, 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below